Sun Pharma Advanced Research Company Limited (SPARC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sun Pharma Advanced Research Company Limited (SPARC) has a cash flow conversion efficiency ratio of 0.336x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-1.16 Billion ≈ $-12.53 Million USD) by net assets (Rs-3.45 Billion ≈ $-37.27 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SPARC company net worth for the company's overall valuation and market capitalisation.
Sun Pharma Advanced Research Company Limited - Cash Flow Conversion Efficiency Trend (2007–2025)
This chart illustrates how Sun Pharma Advanced Research Company Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sun Pharma Advanced Research Company Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sun Pharma Advanced Research Company Limited ranked by their cash flow conversion efficiency. Explore Sun Pharma Advanced Research Company Lim (SPARC) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cogobuy Group
F:7C3
|
-0.057x |
|
Turkiye Sinai Kalkinma Bankasi AS
IS:TSKB
|
0.071x |
|
Danel (Adir Yeoshua) Ltd
TA:DANE
|
0.197x |
|
Chin Hung Int'
KO:002780
|
0.211x |
|
Hemnet Group AB
ST:HEM
|
0.154x |
|
YaGuang Technology Group Co Ltd
SHE:300123
|
-0.035x |
|
Inly Media Co Ltd
SHG:603598
|
-1.087x |
|
Israel Shipyards Ltd
TA:ISHI
|
0.137x |
Annual Cash Flow Conversion Efficiency for Sun Pharma Advanced Research Company Limited (2007–2025)
The table below shows the annual cash flow conversion efficiency of Sun Pharma Advanced Research Company Limited from 2007 to 2025. View Sun Pharma Advanced Research Company Lim (SPARC) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs-2.17 Billion ≈ $-23.46 Million |
Rs-3.60 Billion ≈ $-38.96 Million |
1.661x | +148.66% |
| 2024-03-31 | Rs1.26 Billion ≈ $13.60 Million |
Rs-4.29 Billion ≈ $-46.42 Million |
-3.413x | -2431.86% |
| 2023-03-31 | Rs5.13 Billion ≈ $55.45 Million |
Rs-691.20 Million ≈ $-7.48 Million |
-0.135x | +97.98% |
| 2022-03-31 | Rs312.26 Million ≈ $3.38 Million |
Rs-2.08 Billion ≈ $-22.52 Million |
-6.669x | -838.67% |
| 2021-03-31 | Rs-1.68 Billion ≈ $-18.20 Million |
Rs-1.52 Billion ≈ $-16.43 Million |
0.903x | -92.02% |
| 2020-03-31 | Rs-186.38 Million ≈ $-2.02 Million |
Rs-2.11 Billion ≈ $-22.80 Million |
11.310x | +2048.94% |
| 2019-03-31 | Rs2.96 Billion ≈ $32.04 Million |
Rs-1.72 Billion ≈ $-18.59 Million |
-0.580x | +41.35% |
| 2018-03-31 | Rs1.85 Billion ≈ $19.98 Million |
Rs-1.83 Billion ≈ $-19.77 Million |
-0.989x | -23.37% |
| 2017-03-31 | Rs1.60 Billion ≈ $17.27 Million |
Rs-1.28 Billion ≈ $-13.85 Million |
-0.802x | +45.76% |
| 2016-03-31 | Rs299.03 Million ≈ $3.23 Million |
Rs-442.12 Million ≈ $-4.78 Million |
-1.479x | -272.84% |
| 2015-03-31 | Rs997.99 Million ≈ $10.79 Million |
Rs-395.76 Million ≈ $-4.28 Million |
-0.397x | -249.72% |
| 2014-03-31 | Rs1.39 Billion ≈ $15.06 Million |
Rs368.95 Million ≈ $3.99 Million |
0.265x | +130.12% |
| 2013-03-31 | Rs1.08 Billion ≈ $11.73 Million |
Rs-953.44 Million ≈ $-10.31 Million |
-0.879x | -184.34% |
| 2012-03-31 | Rs-666.09 Million ≈ $-7.20 Million |
Rs-694.49 Million ≈ $-7.51 Million |
1.043x | +134.07% |
| 2011-03-31 | Rs56.23 Million ≈ $608.16K |
Rs25.05 Million ≈ $270.90K |
0.445x | -50.20% |
| 2010-03-31 | Rs141.24 Million ≈ $1.53 Million |
Rs126.34 Million ≈ $1.37 Million |
0.895x | +25.38% |
| 2009-03-31 | Rs356.78 Million ≈ $3.86 Million |
Rs254.54 Million ≈ $2.75 Million |
0.713x | +256.80% |
| 2008-03-31 | Rs448.18 Million ≈ $4.85 Million |
Rs-203.92 Million ≈ $-2.21 Million |
-0.455x | -54787.50% |
| 2007-03-31 | Rs497.01 Million ≈ $5.37 Million |
Rs-412.00K ≈ $-4.46K |
-0.001x | -- |
About Sun Pharma Advanced Research Company Limited
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia th… Read more